Prasugrel (DB06209): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Safety Profile

Section 1: Introduction and Drug Profile

1.1. Overview and Classification

Prasugrel is a potent, orally administered antiplatelet agent belonging to the third generation of the thienopyridine class of drugs.[1] Classified as a small molecule, it functions as a platelet activation and aggregation inhibitor.[3] Its therapeutic effect is achieved through the irreversible antagonism of the P2Y purinoceptor 12 (P2Y12), a key receptor in the process of thrombosis.[3]

Structurally and pharmacologically, prasugrel is related to its thienopyridine predecessors, ticlopidine and clopidogrel.[3] However, it was specifically developed to address certain limitations of these earlier agents, most notably the delayed onset of action and considerable interpatient variability in response observed with clopidogrel.[1] Like clopidogrel, prasugrel is a prodrug, meaning it is biologically inactive upon administration and requires metabolic conversion to exert its pharmacological effect.[3] This biotransformation, however, is more efficient and consistent than that of clopidogrel, leading to a more predictable and potent antiplatelet response.[1]

1.2. Historical Context and Regulatory Approval

Prasugrel was developed by the Japanese pharmaceutical company Daiichi Sankyo Co..[1] For marketing and distribution in North America, Daiichi Sankyo partnered with Eli Lilly and Company.[1] The drug's development pathway culminated in regulatory approvals in major markets, reflecting the clinical need for more effective antiplatelet therapies in high-risk cardiovascular patients.

It first received approval in Europe in February 2009.[1] Shortly thereafter, on July 10, 2009, the United States Food and Drug Administration (FDA) approved prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI).[7] The FDA had granted the drug a priority review, a designation reserved for therapies that may offer significant improvements in treatment, underscoring the perceived potential of prasugrel to advance care beyond the existing standard of clopidogrel.[12] It is currently authorized for use in the United States, Canada, and the European Union.[3]

1.3. Chemical Identification and Properties

The chemical identity of prasugrel is well-defined. Its formal IUPAC name is 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate.[4] During its development and in research literature, it has also been referred to by its developmental codes, CS-747 and LY-640315.[7]

Physically, prasugrel is a crystalline solid that can appear as a light yellow to orange powder or crystal.[9] It has a defined melting point between 120.0 °C and 124.0 °C.[9] Due to its chemical nature, it is considered heat sensitive, and proper storage conditions recommend refrigeration between 0 °C and 10 °C.[9] Under these conditions, the compound demonstrates good stability, remaining viable for at least four years.[13]

1.4. Global Brand Names and Manufacturers

Prasugrel is marketed globally under several brand names. The most common trade names are Effient, used in the United States, and Efient, used in Europe and other regions.[1] Following patent expiry, generic versions of the drug have become available, increasing its accessibility. These include formulations marketed as

Prasugrel Mylan (which was subsequently renamed Prasugrel Viatris) in Europe.[3]

The availability of generic formulations has significant pharmacoeconomic implications, as cost can be a barrier to adherence for potent antiplatelet agents.[16] In countries like Italy, both the originator brand Efient and generic versions such as PRASUGREL TEVA and PRASUGREL VIATRIS are available.[17] Similarly, in Switzerland, Prasugrel-Mepha is a known brand.[17] In India, multiple manufacturers including Celogen Pharma, Intas Pharmaceuticals, and Unichem Laboratories supply generic prasugrel.[17] This diverse market landscape influences prescribing patterns, particularly in the context of off-label use where cost-effectiveness relative to older agents like clopidogrel is a primary consideration.

---

Table 1: Prasugrel Identification and Chemical Properties

Property	Detail	Source(s)
Drug Name	Prasugrel	3
DrugBank ID	DB06209	3
Type	Small Molecule	3
CAS Number	150322-43-3	4
Molecular Formula	C20​H20​FNO3​S	1
Molecular Weight	373.44 g/mol	4
IUPAC Name	5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate	4
Common Synonyms	CS-747, LY-640315	7
Key Brand Names	Effient, Efient, Prasugrel Mylan, Prasugrel Viatris	1
Physical Appearance	Light yellow to yellow to orange powder or crystal	9
Storage Conditions	Refrigerated (0-10°C); Heat Sensitive	9

---

Section 2: Pharmacology: Mechanism of Action and Pharmacodynamics

2.1. The P2Y12 Receptor and Platelet Aggregation Cascade

To understand the action of prasugrel, it is essential to first review the pathophysiology of thrombosis, particularly in the context of acute coronary syndrome (ACS). During an ACS event, the rupture of an atherosclerotic plaque exposes subendothelial components like collagen and von Willebrand factor.[18] This exposure triggers the adhesion of circulating platelets, initiating a complex cascade of platelet activation and aggregation that is central to both normal hemostasis and pathological thrombosis.[11]

Upon activation, platelets release various agonists from their granules, including adenosine diphosphate (ADP) and thromboxane A2 (TXA2).[18] ADP plays a critical role in amplifying and sustaining the platelet response by binding to two key purinergic receptors on the platelet surface: P2Y1 and P2Y12.[11] The binding of ADP to the P2Y12 receptor is particularly crucial; it initiates an intracellular signaling pathway that leads to the conformational activation of the glycoprotein (GP) IIb/IIIa receptor complex. This activated complex then binds to fibrinogen, forming molecular bridges that cross-link adjacent platelets, leading to the formation of a stable platelet aggregate, or thrombus.[8] This thrombus can obstruct coronary blood flow, causing myocardial ischemia and infarction.[11] The P2Y12 receptor is therefore a primary target for antiplatelet therapy.

2.2. Prasugrel's Mechanism of Action

Prasugrel is a prodrug that functions as a potent and selective antagonist of the P2Y12 receptor.[3] Upon oral administration, it is inactive and must undergo metabolic conversion to its active form, a metabolite designated R-138727.[3]

The active metabolite, R-138727, contains a reactive thiol group. This thiol group forms a covalent, disulfide bond with a specific cysteine residue on the extracellular domain of the P2Y12 receptor.[1] This binding is

irreversible, meaning the receptor is permanently inactivated for the entire lifespan of the platelet, which is typically 7 to 10 days.[1] By permanently blocking the P2Y12 receptor, prasugrel's active metabolite prevents ADP from binding and initiating the downstream signaling cascade. This blockade effectively prevents the activation of the GPIIb/IIIa receptor complex, thereby inhibiting ADP-mediated platelet activation and aggregation.[3] The restoration of platelet function after discontinuing prasugrel is not dependent on the drug's clearance from the body but rather on the rate of new platelet production by the bone marrow.[2]

The irreversible nature of this binding is a fundamental characteristic of prasugrel's pharmacology. It ensures a sustained and powerful antiplatelet effect, which is highly effective in preventing thrombotic events such as stent thrombosis.[1] However, this same property presents a significant clinical challenge. In cases of major bleeding or the need for urgent surgery (e.g., coronary artery bypass grafting, CABG), the antiplatelet effect cannot be readily reversed. Management relies on supportive measures and, if necessary, platelet transfusions, as no specific antidote exists.[11]

2.3. Pharmacodynamic Profile

The pharmacodynamic profile of prasugrel is characterized by a rapid onset, high potency, and consistent effect, which collectively distinguish it from its predecessor, clopidogrel.

• Onset of Action: Following a standard 60-mg oral loading dose, inhibition of platelet aggregation begins within 15 to 30 minutes.[18] This rapid onset corresponds with the swift appearance of the active metabolite, R-138727, in the plasma, which reaches its peak concentration ( Cmax​) at approximately 30 minutes.[3] Maximum inhibition of platelet aggregation (IPA) is achieved at around one to two hours post-dose.[2]
• Potency and Consistency: Pharmacodynamic studies have consistently shown that prasugrel achieves a greater and more predictable level of platelet inhibition than clopidogrel.[2] After a 60-mg loading dose, maximum IPA is approximately 80%, and about 90% of patients achieve at least 50% IPA within one hour.[2] With a daily maintenance dose of 10 mg, mean steady-state IPA is about 70%.[2] This potent and consistent response is a direct result of its more efficient metabolic activation, a key advantage that translates into superior clinical efficacy in reducing ischemic events, as demonstrated in landmark clinical trials.[1]
• Duration of Effect: Due to the irreversible binding to the P2Y12 receptor, the antiplatelet effect of a single dose of prasugrel lasts for the entire life of the exposed platelets.[6] Consequently, after discontinuation of the drug, platelet aggregation returns to baseline levels gradually over a period of 5 to 9 days, a timeframe that reflects the turnover rate of the circulating platelet pool.[2]

Section 3: Pharmacokinetics: From Prodrug to Active Metabolite

The pharmacokinetic profile of prasugrel—its absorption, distribution, metabolism, and excretion (ADME)—is central to its clinical utility and explains its advantages over older thienopyridines.

3.1. Absorption

Following oral administration, prasugrel is absorbed rapidly and extensively, with a bioavailability of at least 79%.[2] The absorption process is so efficient that peak plasma concentrations (

Cmax​) of its active metabolite, R-138727, are achieved in approximately 30 minutes.[3] This rapid absorption contributes directly to its fast onset of pharmacodynamic action. Administration can occur with or without food, providing flexibility for patients.[18]

A clinically significant pharmacokinetic interaction has been identified with opioid agonists, such as morphine, which are frequently used for pain relief in the setting of ACS. Co-administration of opioids can delay and reduce the absorption of prasugrel, presumably by slowing gastric emptying.[22] This interaction can blunt the drug's rapid antiplatelet effect, potentially undermining one of its key therapeutic benefits in the acute phase of treatment. This has led to clinical recommendations to consider the use of a parenteral antiplatelet agent in ACS patients who require opioid administration to ensure prompt and reliable platelet inhibition.[22]

3.2. Distribution

Once formed, the active metabolite R-138727 is extensively bound to plasma proteins, with a binding fraction of approximately 98%, primarily to human serum albumin.[2] This high degree of protein binding limits its volume of distribution.

3.3. Metabolism: A Differentiating Pathway

The metabolic activation of prasugrel is a highly efficient, two-step process that represents its most significant pharmacological advantage over clopidogrel.[1]

• Step 1: Esterase-Mediated Hydrolysis: Immediately following absorption, prasugrel is rapidly hydrolyzed by esterases in the intestine (human carboxylesterase 2, hCE2) and liver (carboxylesterase 1, hCE1).[2] This initial step is so rapid that the parent compound, prasugrel, is not detected in plasma.[3] The product of this hydrolysis is an inactive thiolactone intermediate.[2]
• Step 2: Cytochrome P450-Mediated Oxidation: The inactive thiolactone is then converted to the pharmacologically active metabolite, R-138727, via a single oxidation step.[8] This conversion is mediated by several cytochrome P450 (CYP) isoenzymes, primarily CYP3A4 and CYP2B6, with only minor contributions from CYP2C9 and CYP2C19.[2]

This metabolic pathway contrasts sharply with that of clopidogrel, which requires two sequential, CYP-dependent oxidative steps for activation and is heavily reliant on the CYP2C19 isoenzyme.[20] The initial, highly efficient esterase-mediated step and the involvement of multiple CYP enzymes in the second step make prasugrel's activation faster and far less susceptible to the genetic polymorphisms that cause "clopidogrel resistance".[2] This metabolic efficiency is the direct cause of prasugrel's more rapid, potent, and consistent pharmacodynamic effects.[1]

Following its action, the active metabolite is further metabolized into two primary inactive metabolites through S-methylation or conjugation with cysteine.[3]

3.4. Elimination

The elimination of prasugrel's metabolites is relatively rapid. The active metabolite, R-138727, has a mean elimination half-life (t1/2​) of approximately 7.4 hours, with a reported range of 2 to 15 hours.[2] The drug is cleared from the body primarily via renal excretion, with about 68% to 70% of an administered dose being recovered in the urine as inactive metabolites. The remaining 27% is eliminated in the feces.[11] The apparent clearance of the active metabolite ranges from 112 to 166 L/hr.[3]

---

Table 2: Key Pharmacokinetic Parameters of Prasugrel

Parameter	Value / Description	Source(s)
Bioavailability	≥79%	2
Time to Peak Plasma Concentration (Tmax​)	~30 minutes (for active metabolite)	3
Protein Binding (Active Metabolite)	~98% (to human serum albumin)	2
Elimination Half-Life (t1/2​)	~7.4 hours (range: 2–15 hours) (for active metabolite)	3
Primary Metabolizing Enzymes	Intestinal/Hepatic Esterases (hCE2, hCE1); CYP3A4, CYP2B6	2
Route of Elimination	~68-70% renal (as inactive metabolites); ~27% fecal	11

---

Section 4: Clinical Efficacy in Acute Coronary Syndrome (ACS)

The clinical utility of prasugrel is firmly established in the management of ACS, supported by robust evidence from large-scale clinical trials. Its indications are specific and reflect a carefully defined patient population in whom its benefits have been shown to outweigh its risks.

4.1. Approved Clinical Indications

Prasugrel is indicated, in combination with daily aspirin (75 mg to 325 mg), for the secondary prevention of atherothrombotic events in patients with ACS who are to be managed with percutaneous coronary intervention (PCI).[3] This broad indication encompasses the following specific clinical scenarios:

• Unstable Angina (UA) or Non-ST-Elevation Myocardial Infarction (NSTEMI): For patients presenting with UA or NSTEMI who are planned for PCI.[3]
• ST-Elevation Myocardial Infarction (STEMI): For patients presenting with STEMI who are managed with either primary PCI (immediate intervention) or delayed PCI.[3]

The primary goal of therapy is to reduce the rate of thrombotic cardiovascular events, a composite that includes cardiovascular (CV) death, nonfatal myocardial infarction (MI), and nonfatal stroke, as well as the critical outcome of stent thrombosis.[1]

4.2. The TRITON-TIMI 38 Trial: A Pivotal Study

The cornerstone of evidence supporting prasugrel's approval and use is the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel–Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).[5] This landmark trial provided a direct comparison of prasugrel against the then-standard-of-care, clopidogrel.

• Study Design and Population: TRITON-TIMI 38 was a large, multinational, randomized, double-blind trial that enrolled 13,608 patients with moderate-to-high-risk ACS (both UA/NSTEMI and STEMI) for whom PCI was planned.[5] Patients were randomized to receive either prasugrel (a 60-mg loading dose followed by a 10-mg daily maintenance dose) or high-dose clopidogrel (a 300-mg loading dose followed by a 75-mg daily maintenance dose), with both groups also receiving aspirin. The median follow-up period was 14.5 months.[29] A notable feature of the trial's design was that for the UA/NSTEMI cohort, the study drug was not administered until after coronary angiography had been performed, a strategy intended to avoid treating patients who might ultimately be referred for CABG surgery.[24]
• Efficacy Outcomes: The trial met its primary efficacy endpoint, demonstrating the superiority of prasugrel over clopidogrel.
• Primary Composite Endpoint: Prasugrel significantly reduced the composite rate of CV death, nonfatal MI, or nonfatal stroke compared to clopidogrel (9.9% vs. 12.1%; Hazard Ratio 0.81, 95% Confidence Interval [CI] 0.73-0.90; P<0.001).[5] The benefit was primarily driven by a marked reduction in the incidence of nonfatal MI.[5]
• Stent Thrombosis: One of the most striking findings was the profound reduction in stent thrombosis. The rate of definite or probable stent thrombosis was reduced by 52% in the prasugrel group compared to the clopidogrel group (1.1% vs. 2.4%; HR 0.48, 95% CI 0.36-0.64; P<0.001).[1] This benefit was consistent for both bare-metal stents and drug-eluting stents and emerged early, persisting throughout the study.[19] This specific outcome highlights the clinical importance of prasugrel's potent and reliable platelet inhibition, particularly in the high-risk periprocedural period.
• Safety Outcomes: The enhanced efficacy of prasugrel came at the cost of an increased bleeding risk.
• Major Bleeding: The rate of non-CABG-related TIMI Major bleeding, the primary safety endpoint, was significantly higher with prasugrel than with clopidogrel (2.4% vs. 1.8%; HR 1.32, 95% CI 1.03-1.68; P=0.03).[5]
• Life-Threatening and Fatal Bleeding: Prasugrel was also associated with higher rates of life-threatening bleeding (1.4% vs. 0.9%; HR 1.52; P=0.01) and fatal bleeding (0.4% vs. 0.1%; HR 4.19; P=0.002).[25]

The results of TRITON-TIMI 38 established the fundamental clinical paradigm for prasugrel: it is an antiplatelet agent of superior ischemic efficacy but with an attendant increase in bleeding risk. This clear trade-off necessitated a careful analysis of patient subgroups to identify those in whom the balance of benefit and risk was favorable. This analysis led directly to the specific contraindications and warnings that now define the appropriate use of prasugrel in clinical practice, moving away from a "one-size-fits-all" approach to a more stratified, risk-based strategy.[19]

---

Table 3: Summary of Efficacy and Safety Outcomes from the TRITON-TIMI 38 Trial

Outcome	Prasugrel Group (n=6,741)	Clopidogrel Group (n=6,762)	Hazard Ratio (95% CI)	P-value	Source(s)
Primary Efficacy Endpoint
CV Death, Nonfatal MI, or Nonfatal Stroke	9.9%	12.1%	0.81 (0.73 - 0.90)	<0.001	5
Key Secondary Efficacy Endpoints
Nonfatal Myocardial Infarction (MI)	7.3%	9.5%	0.76 (0.67 - 0.85)	<0.001	5
Stent Thrombosis (Definite/Probable)	1.1%	2.4%	0.48 (0.36 - 0.64)	<0.001	19
Cardiovascular (CV) Death	2.1%	2.4%	0.89 (0.73 - 1.08)	0.23	5
Primary Safety Endpoint
TIMI Major Bleeding (non-CABG)	2.4%	1.8%	1.32 (1.03 - 1.68)	0.03	5
Other Safety Endpoints
TIMI Major or Minor Bleeding (non-CABG)	4.5%	3.4%	1.31 (1.11 - 1.56)	0.002	32
Fatal Bleeding	0.4%	0.1%	4.19 (1.58 - 11.11)	0.002	25

---

Section 5: Dosage, Administration, and Use in Specific Populations

The effective and safe use of prasugrel hinges on adherence to specific dosing regimens and careful consideration of patient-specific factors. The recommendations are derived directly from pharmacokinetic studies and the risk-benefit analyses of the TRITON-TIMI 38 trial.

5.1. Standard Dosing Regimen

• Loading Dose: For all indicated patients, treatment with prasugrel should be initiated with a single 60-mg oral loading dose.[11] The timing of this loading dose is critical and differs by ACS presentation. In STEMI patients undergoing primary PCI, the loading dose should be administered as soon as possible.[11] However, for UA/NSTEMI patients, guidelines and the drug's summary of product characteristics recommend that if coronary angiography is performed within 48 hours of admission, the loading dose should be given at the time of PCI, not upstream.[24] This strategy is based on the ACCOAST trial, which showed that pretreatment in NSTEMI patients increased bleeding risk without a corresponding reduction in ischemic events, particularly for those who ultimately required CABG surgery.[24]
• Maintenance Dose: Following the loading dose, the standard maintenance dose is 10 mg taken orally once daily.[11] Prasugrel can be taken with or without food.[18]
• Concomitant Aspirin: Prasugrel therapy must be co-administered with a daily dose of aspirin, typically ranging from 75 mg to 325 mg.[5]
• Duration of Therapy: For patients with ACS treated with PCI, dual antiplatelet therapy (DAPT) with prasugrel and aspirin is generally recommended for up to 12 months.[11] The decision to continue DAPT beyond this period, or to shorten it, should be individualized based on a careful assessment of the patient's ischemic versus bleeding risk.[11]

5.2. Dosing in Specific Populations (Evidence-Driven Adjustments)

The dosing recommendations for prasugrel exemplify a stratified, risk-based approach to antiplatelet therapy. Subgroup analyses from the TRITON-TIMI 38 trial identified specific patient populations where the risk of bleeding with the standard 10-mg dose outweighed the ischemic benefit, leading to specific dose adjustments and warnings.

• Patients with Low Body Weight (<60 kg): Patients weighing less than 60 kg have increased plasma concentrations of prasugrel's active metabolite, leading to a higher risk of bleeding on the standard 10-mg maintenance dose.[19] For these individuals, a reduced maintenance dose of 5 mg once daily is recommended.[3] Pharmacodynamic studies have confirmed that a 5-mg dose in this population provides a level of platelet inhibition comparable to that of a 10-mg dose in patients weighing ≥60 kg.[11]
• Patients of Advanced Age (≥75 years): The use of prasugrel is generally not recommended in patients aged 75 years or older.[3] This is due to a significantly increased risk of bleeding, including fatal and intracranial hemorrhage, with uncertain clinical benefit in this age group.[19] However, an exception may be made for certain high-risk patients, such as those with diabetes or a prior MI, where the potential ischemic benefit may be greater. If treatment is deemed necessary in this age group, a reduced maintenance dose of 5 mg should be prescribed.[25]
• Patients with Renal Impairment: No dosage adjustment is necessary for patients with mild to moderate renal impairment.[11] However, these patients may have an inherently higher bleeding risk, and caution is advised.[19] Clinical experience in patients with end-stage renal disease (ESRD) is limited, and these patients should be treated with caution.[11]
• Patients with Hepatic Impairment: No dose modification is required for patients with mild to moderate hepatic impairment (Child-Pugh Class A and B).[11] Prasugrel has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is contraindicated in this group due to the high risk of bleeding.[24]

---

Table 4: Dosing and Administration Guidelines for Prasugrel

Patient Population	Loading Dose	Maintenance Dose	Key Clinical Notes & Rationale	Source(s)
Standard ACS Patient (<75 years, ≥60 kg)	60 mg, once	10 mg, once daily	Standard regimen based on TRITON-TIMI 38. Administer with aspirin.	11
Low Body Weight (<60 kg)	60 mg, once	5 mg, once daily	Increased drug exposure and bleeding risk with 10 mg dose. 5 mg dose provides similar platelet inhibition.	3
Advanced Age (≥75 years)	60 mg, once	Generally not recommended. If used, consider 5 mg once daily.	Increased risk of fatal and intracranial bleeding with uncertain benefit. Exception may be considered for high-risk patients (diabetes, prior MI).	3
Prior TIA or Stroke	Contraindicated	Contraindicated	Net harm demonstrated in TRITON-TIMI 38 due to a significant increase in intracranial hemorrhage.	24
Renal Impairment	60 mg, once	10 mg, once daily	No dose adjustment needed, but caution in moderate-to-severe impairment and ESRD due to higher baseline bleeding risk.	11
Hepatic Impairment	60 mg, once	10 mg, once daily (Mild-Moderate)	No adjustment for Child-Pugh A/B. Contraindicated in severe impairment (Child-Pugh C).	11

---

Section 6: Safety Profile: Bleeding Risk, Contraindications, and Adverse Events

The potent antiplatelet activity of prasugrel, while beneficial for preventing ischemic events, is intrinsically linked to a heightened risk of bleeding. A thorough understanding of its safety profile, contraindications, and warnings is therefore essential for its judicious clinical use.

6.1. FDA Boxed Warning: Bleeding Risk

Prasugrel's prescribing information includes a boxed warning, the most serious type of warning issued by the U.S. FDA. This warning explicitly states that prasugrel can cause significant, and sometimes fatal, bleeding.[19] The boxed warning serves to alert prescribers to the critical need for careful patient selection and to highlight the populations in which the drug should not be used. Specifically, the warning emphasizes that prasugrel is contraindicated in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke, and that it is generally not recommended for patients aged 75 years or older.[25]

6.2. Absolute Contraindications

The use of prasugrel is strictly prohibited in certain patient populations where the risk of harm has been shown to clearly outweigh any potential benefit.

• Prior Transient Ischemic Attack (TIA) or Stroke: This is a firm contraindication based on evidence of net harm from the TRITON-TIMI 38 trial. In the subgroup of patients with a prior TIA or stroke, those treated with prasugrel experienced a significantly higher rate of subsequent stroke (6.5%) compared to those on clopidogrel (1.2%). Critically, this increase was driven by a substantial rise in intracranial hemorrhage (ICH), which occurred in 2.3% of prasugrel-treated patients in this subgroup.[24] Any patient who experiences a TIA or stroke while on prasugrel therapy should generally have the medication discontinued.[32]
• Active Pathological Bleeding: Prasugrel must not be used in patients with any form of active pathological bleeding, such as a bleeding peptic ulcer or intracranial hemorrhage.[24]
• Known Hypersensitivity: The drug is contraindicated in patients with a history of hypersensitivity, including anaphylaxis, to prasugrel or any of the product's components.[32] Reports have also noted hypersensitivity reactions, including angioedema, in patients with a prior allergy to other thienopyridines (e.g., clopidogrel), suggesting a potential for cross-reactivity.[25]

6.3. Warnings and Precautions

Beyond the absolute contraindications, several clinical situations warrant significant caution.

• Surgery-Related Bleeding: The risk of bleeding is substantially increased in patients undergoing surgery, particularly major procedures like coronary artery bypass graft (CABG) surgery. In TRITON-TIMI 38, the rate of CABG-related TIMI Major or Minor bleeding was 14.1% in the prasugrel group versus 4.5% in the clopidogrel group.[32] To mitigate this risk, guidelines recommend that prasugrel be discontinued at least 7 days prior to any planned surgery, including dental procedures, if clinically feasible.[19] Prasugrel should not be initiated in patients who are likely to undergo urgent CABG.[19]
• Propensity to Bleed: Caution should be exercised in patients with an underlying propensity to bleed. This includes individuals with recent trauma or surgery, recent or recurrent gastrointestinal (GI) bleeding, active peptic ulcer disease, severe hepatic impairment, or moderate-to-severe renal impairment.[19]
• Thrombotic Thrombocytopenic Purpura (TTP): TTP is a rare but life-threatening adverse event that has been reported in patients taking prasugrel and other thienopyridines. TTP is a medical emergency characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological findings, fever, and renal dysfunction. It requires immediate recognition and treatment.[19]

6.4. Common and Serious Adverse Reactions

• Bleeding: As expected, bleeding is the most commonly reported adverse reaction associated with prasugrel therapy. This can range from minor events like increased bruising and epistaxis (nosebleeds) to severe, life-threatening, and fatal hemorrhages.[5] Patients should be counseled on the signs of serious bleeding, such as hematuria (pink, red, or brown urine), hematemesis (vomiting blood or material that looks like coffee grounds), and melena (black, tarry stools).[36]
• Other Adverse Effects: Besides bleeding, other reported adverse effects include headache, diarrhea, nausea, back pain, and skin rash.[38] Hypersensitivity reactions, including pruritus, rash, and angioedema (swelling of the face, lips, tongue, or throat), can also occur and require immediate medical attention.[25]

6.5. Management of Bleeding and Toxicity

A significant challenge in managing prasugrel-related complications is the lack of a specific reversal agent or antidote.[11] In cases of overdose or severe bleeding, management is primarily supportive. While platelet transfusion is a theoretical option to restore hemostasis, its effectiveness may be limited, particularly if administered shortly after a loading dose (within 6 hours) or maintenance dose (within 4 hours), as newly transfused platelets will be rapidly inhibited by the circulating active metabolite.[11]

Given the increased risk of stent thrombosis, MI, and death associated with premature discontinuation of therapy, bleeding should be managed without stopping prasugrel whenever possible, especially in the first few weeks following an ACS event.[19]

---

Table 5: Summary of Contraindications and Key Warnings for Prasugrel

Category	Condition / Patient Group	Clinical Recommendation / Action	Rationale / Evidence	Source(s)
Boxed Warning	General Bleeding Risk	Can cause significant, sometimes fatal, bleeding.	Based on primary safety endpoint of TRITON-TIMI 38.	25
Contraindication	Prior TIA or Stroke	Do not use.	Evidence of net harm; significant increase in intracranial hemorrhage (2.3% vs. 0.3% in patients with prior stroke/TIA without ICH).	19
Contraindication	Active Pathological Bleeding	Do not use.	Potent antiplatelet effect will exacerbate active bleeding (e.g., peptic ulcer, ICH).	24
Contraindication	Hypersensitivity	Do not use.	Risk of anaphylaxis or angioedema. Potential cross-reactivity with other thienopyridines.	25
Warning / Precaution	Age ≥75 years	Generally not recommended.	Increased risk of fatal and intracranial bleeding with uncertain benefit.	19
Warning / Precaution	Body Weight <60 kg	Consider 5 mg maintenance dose.	Increased drug exposure and bleeding risk on standard 10 mg dose.	19
Warning / Precaution	Planned Surgery (e.g., CABG)	Discontinue at least 7 days prior. Do not start in patients likely to undergo urgent CABG.	Significantly increased risk of major peri-operative bleeding.	19
Warning / Precaution	Propensity to Bleed	Use with caution.	Increased risk in patients with recent trauma, GI bleeding, or severe hepatic/renal impairment.	19
Warning / Precaution	Thrombotic Thrombocytopenic Purpura (TTP)	Monitor for signs/symptoms; TTP is a medical emergency.	Rare but serious and potentially fatal adverse event reported with prasugrel.	19

---

Section 7: Drug Interactions and Pharmacogenomic Considerations

Prasugrel's interaction profile is a critical aspect of its clinical characterization, particularly in how it compares to other antiplatelet agents. Its interactions can be broadly categorized as pharmacodynamic (related to additive effects on hemostasis) and pharmacokinetic (related to effects on its ADME).

7.1. Pharmacodynamic Interactions (Increased Bleeding Risk)

The most significant drug interactions for prasugrel are pharmacodynamic, involving concomitant use of other medications that affect hemostasis. These interactions are predictable based on the drug's mechanism of action and lead to an additive risk of bleeding.

• Anticoagulants: The concurrent use of prasugrel with oral anticoagulants like warfarin or direct oral anticoagulants (DOACs) such as apixaban, or with parenteral anticoagulants like heparin, significantly elevates the risk of major bleeding. Such combinations should generally be avoided or used with extreme caution and intensive monitoring.[3]
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Chronic co-administration of NSAIDs (e.g., ibuprofen, naproxen) with prasugrel can increase the risk of gastrointestinal and other bleeding due to the antiplatelet effects of both drug classes. This combination should be used cautiously.[25]
• Other Antiplatelet Agents: While prasugrel is intended for use with aspirin, combining it with other potent antiplatelet agents, such as glycoprotein IIb/IIIa inhibitors (e.g., abciximab), further increases bleeding risk, although this combination is sometimes used in the acute setting of high-risk PCI.[3]

7.2. Pharmacokinetic Interactions

Prasugrel has a relatively favorable pharmacokinetic interaction profile, especially when compared to clopidogrel.

• Opioid Agonists: A clinically important interaction exists with opioid agonists (e.g., morphine, oxycodone). These drugs can slow gastric emptying, which in turn delays and reduces the absorption of orally administered prasugrel and the formation of its active metabolite. This can compromise its rapid onset of action, a key advantage in the ACS setting. For patients requiring opioids, clinicians should be aware of this potential for a blunted antiplatelet effect and may consider parenteral antiplatelet therapy.[22]
• Drugs Affecting CYP Enzymes: Prasugrel's metabolism is primarily mediated by CYP3A4 and CYP2B6.[2] However, its clinical effect appears largely unaffected by drugs that inhibit or induce these pathways. For instance, co-administration with ketoconazole, a potent CYP3A inhibitor, decreased the Cmax​ of the active metabolite but did not significantly alter its overall exposure (AUC) or its inhibitory effect on platelet aggregation.[34] Therefore, common CYP3A inhibitors like diltiazem, clarithromycin, or grapefruit juice are not expected to have a clinically significant effect on prasugrel's efficacy.[34]
• Drugs Elevating Gastric pH: The interaction between clopidogrel and proton pump inhibitors (PPIs) has been a subject of significant clinical concern. In contrast, prasugrel's efficacy is not meaningfully impacted by acid-suppressing agents. Co-administration with PPIs (e.g., lansoprazole) or H2-receptor antagonists (e.g., ranitidine) may slightly decrease the Cmax​ of the active metabolite, but it does not change the AUC or the extent of platelet inhibition. Therefore, prasugrel can be safely and effectively co-administered with these agents when clinically indicated.[2]

7.3. Pharmacogenomics: The CYP2C19 Advantage

Perhaps the most significant differentiating feature of prasugrel's pharmacology is its relative independence from the influence of CYP2C19 genetic polymorphisms. This stands in stark contrast to clopidogrel, whose activation is highly dependent on the CYP2C19 enzyme.

• Clopidogrel's Limitation: A significant portion of the population carries loss-of-function alleles for the CYP2C19 gene, rendering them "poor metabolizers" of clopidogrel. In these individuals, the conversion of clopidogrel to its active metabolite is impaired, leading to lower levels of platelet inhibition and a higher risk of adverse cardiovascular events, including stent thrombosis. This issue is significant enough that the FDA has issued a boxed warning for clopidogrel regarding this genetic variability.[2]
• Prasugrel's Reliability: Prasugrel's metabolic activation pathway, which relies on initial hydrolysis by esterases and subsequent oxidation by multiple CYP enzymes (primarily CYP3A4 and CYP2B6, with only minor involvement of CYP2C19), makes it far less vulnerable to this genetic variation.[2] The FDA-approved label for prasugrel explicitly states that genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 has no clinically relevant effect on its pharmacokinetics or its inhibition of platelet aggregation.[34]

This pharmacogenomic advantage is a cornerstone of prasugrel's value proposition. It provides a more consistent and predictable antiplatelet effect across a broad patient population, effectively overcoming the problem of "clopidogrel resistance" and obviating the need for routine genetic testing to guide therapy selection.[2]

Section 8: Comparative Analysis with Other Oral P2Y12 Inhibitors

The selection of an oral P2Y12 inhibitor is a critical decision in the management of ACS. Prasugrel's place in therapy is best understood through direct comparison with its main alternatives: clopidogrel and ticagrelor.

8.1. Prasugrel vs. Clopidogrel

The comparison between prasugrel and clopidogrel is well-defined by the TRITON-TIMI 38 trial and numerous pharmacodynamic studies.

• Efficacy: Prasugrel is unequivocally more potent and effective than clopidogrel for its approved indication. It provides a more rapid, consistent, and profound inhibition of platelet aggregation.[2] This translates into superior clinical outcomes, with a significant reduction in the composite of CV death, MI, or stroke, and a particularly robust reduction in the risk of stent thrombosis in ACS patients undergoing PCI.[5]
• Safety: The superior efficacy of prasugrel is counterbalanced by a significantly higher risk of major bleeding, including life-threatening and fatal bleeding events, when compared to clopidogrel.[5]
• Pharmacology and Pharmacogenomics: Prasugrel's more efficient metabolic activation pathway bypasses the critical reliance on the CYP2C19 enzyme that limits clopidogrel's effectiveness in a substantial portion of the population. This makes prasugrel a more reliable agent, providing predictable antiplatelet effects without the need for genetic testing.[2]

In essence, prasugrel represents a trade-off: greater protection against ischemic events at the cost of increased bleeding. This profile makes it a preferred agent for patients at high ischemic risk and low bleeding risk, but an inappropriate choice for those with contraindications or high-risk features for bleeding.

8.2. Prasugrel vs. Ticagrelor: The Battle of the Potent P2Y12s

The choice between the two potent P2Y12 inhibitors, prasugrel and ticagrelor, is more nuanced and remains a subject of ongoing clinical debate.

• Pharmacological Differences: The two drugs belong to different chemical classes and have distinct mechanisms. Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor.[2] Ticagrelor is a cyclopentyl-triazolo-pyrimidine, a direct-acting agent that reversibly binds to the P2Y12 receptor at a site distinct from the ADP binding site.[23] Ticagrelor does not require metabolic activation to exert its effect.
• Head-to-Head Clinical Evidence:
• ISAR-REACT 5 Trial: This large, investigator-initiated, randomized trial is the most significant head-to-head comparison. It enrolled 4,018 ACS patients planned for invasive management and found that a prasugrel-based strategy was superior to a ticagrelor-based strategy in reducing the primary composite endpoint of all-cause death, MI, or stroke at one year (6.9% vs. 9.3%; HR 0.74; P=0.006).[44] Importantly, this ischemic benefit was achieved without a statistically significant increase in the rate of major bleeding (BARC type 3-5 bleeding: 4.8% vs. 5.4%; HR 0.89; P=0.46).[45] The benefit appeared most pronounced in patients with STEMI.[44]
• Other Evidence: The picture is less clear when considering all available data. A large network meta-analysis of 12 randomized trials found no significant differences between prasugrel and ticagrelor for mortality, MI, stroke, or major bleeding, although it did note that only ticagrelor showed a statistically significant mortality benefit when compared indirectly to clopidogrel.[30] Several real-world observational studies, including a large analysis from the SWEDEHEART registry, have also found similar efficacy and safety profiles between the two drugs at one-year follow-up.[42]
• Interpreting the Discrepancies: The superiority of prasugrel in ISAR-REACT 5 may be partially attributable to its trial design. In the NSTEMI cohort, ticagrelor was given as an upstream pretreatment, while the prasugrel loading dose was administered only after coronary angiography was performed. This "treatment strategy" comparison, rather than a pure drug-to-drug comparison, may have favored prasugrel by avoiding its administration in patients who did not undergo PCI or were sent for CABG, thereby reducing bleeding complications in that arm.[42] Additionally, some studies suggest that treatment discontinuation rates may be higher with ticagrelor, often due to its characteristic side effect of dyspnea, which is not associated with prasugrel.[42]

The current body of evidence suggests that while ISAR-REACT 5 provides strong support for prasugrel, particularly in STEMI, the two agents may be considered broadly comparable for many ACS patients. The ultimate choice may depend on local protocols, patient-specific factors (e.g., ACS subtype, bleeding risk, tolerability), and cost.

---

Table 6: Comparative Profile of Oral P2Y12 Inhibitors

Characteristic	Clopidogrel	Prasugrel	Ticagrelor
Drug Class	Thienopyridine	Thienopyridine	Cyclopentyl-triazolo-pyrimidine
Mechanism	Irreversible P2Y12 antagonist	Irreversible P2Y12 antagonist	Reversible P2Y12 antagonist
Prodrug Status	Yes, requires two-step activation	Yes, requires two-step activation	No, direct-acting
Metabolic Pathway	Heavily dependent on CYP2C19	Esterase hydrolysis then CYP3A4/2B6	Primarily CYP3A4 (for clearance)
Onset of Action	Slow (2-6 hours)	Rapid (~30 minutes)	Rapid (~30 minutes)
Impact of CYP2C19 Genetics	Significant; reduced effect in poor metabolizers (FDA Boxed Warning)	No clinically relevant effect	No clinically relevant effect
Key Trial vs. Clopidogrel	CURE (vs. placebo)	TRITON-TIMI 38	PLATO
Efficacy vs. Clopidogrel in ACS-PCI	Inferior	Superior (reduced MI, stent thrombosis)	Superior (reduced CV death, MI)
Major Bleeding vs. Clopidogrel	Baseline	Increased risk	Increased risk
Dosing (LD/MD)	300-600 mg / 75 mg daily	60 mg / 10 mg (or 5 mg) daily	180 mg / 90 mg twice daily
Unique Side Effect	-	-	Dyspnea
Source(s)	2	2	23

---

Section 9: Role in Clinical Practice and Emerging Applications

Prasugrel's established efficacy and well-characterized safety profile have secured its role in major international guidelines. However, its use continues to evolve, with significant off-label application and investigation into novel indications.

9.1. Place in Clinical Guidelines

Both the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) guidelines endorse the use of a potent P2Y12 inhibitor—either prasugrel or ticagrelor—in preference to clopidogrel for patients with ACS undergoing PCI, provided there are no contraindications.[16] This is a Class I (strong) recommendation, reflecting the high-quality evidence from trials like TRITON-TIMI 38 and PLATO.

The guidelines strongly emphasize the importance of adhering to prasugrel's specific safety criteria. This includes the absolute contraindication in patients with a history of stroke or TIA and the general non-recommendation for patients aged 75 or older or those with a body weight under 60 kg.[11] For ACS patients treated with a stent, dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor is recommended for a minimum of 12 months, unless a high bleeding risk warrants consideration of a shorter duration.[11]

9.2. Off-Label Use in Stable Coronary Artery Disease (SCAD)

A significant discrepancy exists between guideline recommendations and real-world clinical practice regarding the use of prasugrel in patients with stable coronary artery disease (SCAD), also known as chronic coronary syndromes (CCS), who undergo elective PCI.

• Guideline Status: For elective PCI in SCAD, clopidogrel remains the only P2Y12 inhibitor with a Class I recommendation, based on long-standing evidence of its benefit in this lower-risk setting.[16] Prasugrel and ticagrelor carry only a Class IIb (weak) recommendation, acknowledging that their use might be considered but is based on limited data and expert opinion rather than robust clinical trial evidence.[49]
• Observed Practice and Evidence Gap: Despite these guidelines, registry data show a substantial and increasing trend of off-label prasugrel and ticagrelor use in the SCAD-PCI population.[16] One analysis of a large U.S. insurance database found that by 2016, over one-third of patients undergoing PCI for non-ACS indications received one of these more potent agents.[16] This practice is likely driven by clinicians' desire to minimize the risk of periprocedural thrombotic complications, such as periprocedural MI or stent thrombosis, especially in patients perceived to have high-risk features (e.g., complex anatomy like bifurcation or left main stenting, diabetes).[49]
• Rationale and Clinical Trials: Pharmacodynamic studies have confirmed that a loading dose of prasugrel achieves more rapid and potent platelet inhibition than clopidogrel in SCAD patients undergoing PCI.[48] However, these studies were not powered to assess clinical outcomes. Trials designed to investigate this question, such as TRIGGER-PCI, have been unable to demonstrate a clear clinical benefit for this strategy, largely due to very low event rates in the modern era of drug-eluting stents.[51] Thus, the routine off-label use of prasugrel in SCAD remains controversial, as it exposes a lower-risk population to increased bleeding potential and higher costs without proven clinical superiority over clopidogrel.[16] The ongoing ALPHEUS trial is expected to provide more definitive data on this topic.[16]

9.3. Investigational Uses

The potent antiplatelet properties of prasugrel have prompted investigation into its use beyond coronary artery disease.

• Sickle Cell Disease (SCD): Platelet activation is known to contribute to the pathophysiology of vaso-occlusive crises (VOCs) in SCD. This has led to the investigation of prasugrel as a potential therapy to prevent these painful and debilitating events. A completed Phase 2 clinical trial (NCT01476696) has evaluated the use of prasugrel in pediatric patients with SCD.[52] Reflecting this potential, prasugrel has received an orphan drug designation from regulatory bodies for the treatment of SCD, highlighting an intriguing area of drug repurposing.[22]
• Other Clinical Trials: Numerous Phase 4 post-marketing trials have been conducted to refine the use of prasugrel. These studies have explored optimal strategies for switching to and from other antiplatelet agents (e.g., clopidogrel, cangrelor), phenotype-based dosing strategies in specific ethnic groups like Asians, and other pleiotropic effects of the drug.[46]

Section 10: Conclusion: A Potent Agent Requiring Judicious Use

10.1. Summary of Prasugrel's Profile

Prasugrel is a third-generation thienopyridine antiplatelet agent that represents a significant evolution in the management of atherothrombotic disease. Its defining feature is its ability to produce rapid, potent, and consistent inhibition of platelet aggregation through the irreversible blockade of the P2Y12 receptor.[2] Its highly efficient metabolic activation pathway circumvents the key limitations of clopidogrel, most notably the impact of CYP2C19 genetic polymorphisms, ensuring a reliable therapeutic effect across a diverse patient population.[40]

10.2. The Core Clinical Dilemma: Efficacy vs. Safety

The clinical profile of prasugrel is defined by a clear and well-established trade-off. In its approved indication—patients with acute coronary syndrome managed with percutaneous coronary intervention—prasugrel has demonstrated unequivocal superiority over clopidogrel in reducing the risk of major ischemic events, including the particularly feared complication of stent thrombosis.[5] This enhanced efficacy, however, is inextricably linked to a statistically significant and clinically meaningful increase in the risk of major and fatal bleeding.[5] This duality forms the central dilemma for clinicians: how to maximize the drug's ischemic benefit while minimizing its hemorrhagic harm.

10.3. The Imperative of Patient Selection

The resolution to this dilemma lies in meticulous and evidence-based patient selection. The successful and safe use of prasugrel is not a matter of universal application but of targeted therapy. Adherence to the absolute contraindications—a history of prior stroke or TIA and the presence of active pathological bleeding—is non-negotiable and is based on trial data showing net harm in these groups.[32] Similarly, the warnings regarding patients of advanced age (

≥75 years) and low body weight (<60 kg) must be respected, with dose reduction or avoidance being critical risk-mitigation strategies.[19] Prasugrel is a tool best reserved for patients with a high ischemic risk profile and a low bleeding risk profile.

10.4. Future Directions and Unanswered Questions

Despite its established role, several questions regarding prasugrel's optimal use persist. The comparative effectiveness against ticagrelor remains a subject of debate; while the ISAR-REACT 5 trial favored prasugrel, the totality of evidence suggests that the choice may be nuanced, potentially depending on ACS subtype (STEMI vs. NSTEMI), individual patient characteristics, and treatment strategy.[30] Furthermore, the widespread off-label use of prasugrel in stable coronary artery disease patients undergoing elective PCI represents a significant evidence-practice gap. While pharmacodynamically plausible, this strategy lacks robust clinical outcome data to support its routine use over the safer and more economical clopidogrel.[16] Future trials are needed to clarify its role in this lower-risk population.

10.5. Final Verdict

Prasugrel is a powerful and indispensable agent in the modern cardiovascular armamentarium. Its introduction provided a highly effective solution to the challenge of high on-treatment platelet reactivity seen with clopidogrel, significantly reducing the burden of ischemic events in high-risk ACS patients. However, its potency is a double-edged sword that demands respect and careful clinical judgment. Optimal patient outcomes with prasugrel can only be achieved when its proven benefits are deliberately and individually weighed against its known risks, perfectly embodying the core principle of personalized medicine: prescribing the right drug for the right patient at the right time.

Works cited

1. 150322-43-3 | CAS DataBase - ChemicalBook, accessed July 23, 2025, https://www.chemicalbook.com/CASEN_150322-43-3.htm
2. Prasugrel - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Prasugrel
3. Prasugrel: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB06209
4. Prasugrel | CAS 150322-43-3 | SCBT - Santa Cruz Biotechnology, accessed July 23, 2025, https://www.scbt.com/p/prasugrel-150322-43-3
5. PRASUGREL OBJECTIVE: ABBREVIATIONS: MECHANISM OF ACTION: INDICATION: - Thrombosis Canada, accessed July 23, 2025, https://thrombosiscanada.ca/guides/pdfs/Prasugrel.pdf
6. www.ncbi.nlm.nih.gov, accessed July 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557427/#:~:text=Go%20to%3A-,Mechanism%20of%20Action,and%20aggregation%20induced%20by%20ADP.
7. Prasugrel | C20H20FNO3S | CID 6918456 - PubChem, accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Prasugrel
8. What is the mechanism of Prasugrel Hydrochloride? - Patsnap Synapse, accessed July 23, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-prasugrel-hydrochloride
9. Prasugrel 150322-43-3 | Tokyo Chemical Industry (India) Pvt. Ltd., accessed July 23, 2025, https://www.tcichemicals.com/IN/en/p/P2040
10. Effient(TM) is Now Available in Pharmacies | Eli Lilly and Company, accessed July 23, 2025, https://investor.lilly.com/news-releases/news-release-details/effienttm-now-available-pharmacies
11. Prasugrel - StatPearls - NCBI Bookshelf, accessed July 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557427/
12. Effient (prasugrel) FDA Approval History - Drugs.com, accessed July 23, 2025, https://www.drugs.com/history/effient.html
13. Prasugrel (CS 747, LY640315, CAS Number: 150322-43-3) | Cayman Chemical, accessed July 23, 2025, https://www.caymanchem.com/product/14278/prasugrel
14. Prasugrel (Effient): Uses, Side Effects, Alternatives & More - GoodRx, accessed July 23, 2025, https://www.goodrx.com/prasugrel/what-is
15. Prasugrel Viatris (previously Prasugrel Mylan) | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/prasugrel-viatris
16. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009–2016 | Circulation, accessed July 23, 2025, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.007434
17. Prasugrel (Effient) | All | Licensing, EU CTD Dossiers, Formulation ..., accessed July 23, 2025, https://www.pharmacompass.com/fdf-licensing-available-formulations-dossiers/prasugrel-effient
18. Prasugrel (Effient), an Adenosine Diphosphate Receptor Antagonist for the Treatment Of Acute Coronary Syndrome - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2799124/
19. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022307s016lbl.pdf
20. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5132138/
21. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/19698014/
22. Effient (prasugrel) dosing, indications, interactions, adverse effects, and more, accessed July 23, 2025, https://reference.medscape.com/drug/effient-prasugrel-999200
23. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta‐analysis, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7373703/
24. JAMP Prasugrel, accessed July 23, 2025, https://pdf.hres.ca/dpd_pm/00057073.PDF
25. EFFIENT (prasugrel) tablets Label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022307s007lbl.pdf
26. ST Elevated Myocardial Infarction Completed Phase 4 Trials for Prasugrel (DB06209), accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0058604/clinical_trials/DB06209?phase=4&status=completed
27. Clinical implications of the results of recent atherothrombotic trials on patient management - Oxford Academic, accessed July 23, 2025, https://academic.oup.com/eurheartjsupp/article/10/suppl_I/I30/414214
28. An Algorithm for use of Prasugrel (Effient) in Patients Undergoing Cardiac Catheterization and Percutaneous Coronary Intervention - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3039920/
29. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance - NICE, accessed July 23, 2025, https://www.nice.org.uk/guidance/ta317/documents/prasugrel-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndrome-review-of-ta182-final-appraisal-document2
30. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute ..., accessed July 23, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046786
31. Prasugrel in Cardiology: A Comprehensive Guide - Number Analytics, accessed July 23, 2025, https://www.numberanalytics.com/blog/prasugrel-in-cardiology-comprehensive-guide
32. Effient (prasugrel) 5 mg. and 10 mg. Tablets - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022307Orig1s008.pdf
33. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry, accessed July 23, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.114.000849
34. Drugs@FDA: Drug Product Effient (Prasugrel hydrochloride), NDA022307, Eli Lilly and Company - PharmGKB, accessed July 23, 2025, https://www.pharmgkb.org/literature/15101925
35. Prasugrel Disease Interactions - Drugs.com, accessed July 23, 2025, https://www.drugs.com/disease-interactions/prasugrel.html
36. Prasugrel (Effient): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 23, 2025, https://www.webmd.com/drugs/2/drug-152680/prasugrel-oral/details
37. Effient (prasugrel) tablets label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf
38. Prasugrel (oral route) - Side effects & dosage - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/prasugrel-oral-route/description/drg-20073095
39. Prasugrel (Effient): Uses & Side Effects - Cleveland Clinic, accessed July 23, 2025, https://my.clevelandclinic.org/health/drugs/20710-prasugrel-oral-tablets
40. Comparison of Clopidogrel and Prasugrel for Prevention of Ischemic Events in Acute Coronary Syndrome - American College of Cardiology, accessed July 23, 2025, https://www.acc.org/latest-in-cardiology/articles/2017/06/22/06/24/comparison-of-clopidogrel-and-prasugrel-for-prevention-of-ischemic-events-in-acs
41. Annotation of FDA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5, accessed July 23, 2025, https://www.pharmgkb.org/labelAnnotation/PA166104917
42. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety, accessed July 23, 2025, https://www.mdpi.com/2305-6320/12/2/13
43. Prasugrel versus ticagrelor in patients with myocardial infarction ..., accessed July 23, 2025, https://heart.bmj.com/content/107/14/1145
44. Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39621344/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=16koWIt7v5kNs8rDlsDGcQuYlCswHLvXS02M7qn1ETDmPUMcie&fc=None&ff=20241208065247&v=2.18.0.post9+e462414
45. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes ..., accessed July 23, 2025, https://www.the-hospitalist.org/hospitalist/article/37445/cardiology/ticagrelor-or-prasugrel-in-patients-with-acute-coronary-syndromes/
46. Prasugrel Completed Phase 4 Trials for Coronary Artery Disease (CAD) / Acute Coronary Syndrome (ACS) Treatment - DrugBank, accessed July 23, 2025, https://go.drugbank.com/drugs/DB06209/clinical_trials?conditions=DBCOND0032938%2CDBCOND0032937&phase=4&purpose=treatment&status=completed
47. Dual antiplatelet therapy for the general cardiologist: recent evidence, balancing ischaemic and bleeding risk - European Society of Cardiology, accessed July 23, 2025, https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/dual-antiplatelet-therapy-for-the-general-cardiologist-recent-evidence-balanci
48. Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention∗ | JACC, accessed July 23, 2025, https://www.jacc.org/doi/10.1016/j.jcin.2015.11.022
49. Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?∗ | JACC, accessed July 23, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2015.11.043
50. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes | EuroIntervention, accessed July 23, 2025, https://eurointervention.pcronline.com/article/ticagrelor-or-prasugrel-versus-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-for-chronic-coronary-syndromes
51. New Study Looks at Prasugrel vs. Clopidogrel After DES Implantation, accessed July 23, 2025, https://www.acc.org/latest-in-cardiology/articles/2012/04/19/12/26/trigger-pci
52. Prasugrel Completed Phase 2 Trials for Sickle Cell Disease (SCD) Treatment - DrugBank, accessed July 23, 2025, https://go.drugbank.com/drugs/DB06209/clinical_trials?conditions=DBCOND0128712&phase=2&purpose=treatment&status=completed
53. Hemorrhagic episodes Completed Phase 4 Trials for Prasugrel (DB06209) - DrugBank, accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0093784/clinical_trials/DB06209?phase=4&status=completed
54. Prasugrel Completed Phase 4 Trials for Acute Coronary Syndrome (ACS) Treatment, accessed July 23, 2025, https://go.drugbank.com/drugs/DB06209/clinical_trials?conditions=DBCOND0032938&phase=4&purpose=treatment&status=completed
55. Expert Consensus on Switching Antiplatelet Therapies - American College of Cardiology, accessed July 23, 2025, https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/12/33/international-expert-consensus-on-switching-platelet